Skip to content

Oridonin

Oridonin is an ent-kaurane diterpenoid isolated from Isodon rubescens (also reported as Rabdosia rubescens). Its gout-relevant hypothesis is direct interruption of NLRP3–NEK7 assembly. The evidence supports a preclinical mechanism and a gout-relevant experiment; it does not establish human gout efficacy, a dose, or a preferred formulation.

Exploitable weakness

He et al. reported that oridonin covalently modified NLRP3 at Cys279 and blocked the NLRP3–NEK7 interaction, with inflammasome effects in biochemical, cellular, and animal systems (In Vitro + Animal Model; PMID 29959312). The result is material-, assay-, and model-specific.

The source supports a direct NLRP3 mechanism. It does not show:

  • efficacy in human gout;
  • useful exposure in synovial macrophages;
  • equivalence among purified oridonin, plant extracts, and analogs;
  • selectivity or safety under chronic exposure;
  • or additivity with another NLRP3 or upstream-pathway candidate.

Sourcing and identity

Candidate materials include purified oridonin, compositionally characterized I. rubescens extracts, and synthetic derivatives. They are not interchangeable. A study should record:

  • exact chemical identity and stereochemistry;
  • purity and co-constituents;
  • lot, solvent, stability, and storage;
  • formulation and measured free exposure;
  • and any derivative-specific covalent-reactivity or off-target data.

Traditional use can motivate multilingual source discovery. It does not establish the identity, exposure, safety, or efficacy of isolated oridonin. Apply the source and material standards in TCM × modern rigor.

Exposure and safety boundary

The current source set does not establish a human gout-active concentration or an oral regimen. Values reported in different biochemical and cellular systems cannot be ranked or converted into a human dose without a matched assay and pharmacokinetic bridge.

Covalent target engagement makes selectivity and reversibility important safety questions. A useful translation package would measure parent and metabolites, free concentration in the intended compartment, NLRP3 engagement, off-target cysteine reactivity, hepatic and immune effects, and preservation of relevant non-NLRP3 host-defense pathways.

Research conjecture

Research conjecture — exact oridonin target engagement may suppress MSU-triggered inflammasome output

Grounded premises: Oridonin covalently modified NLRP3 Cys279, disrupted NLRP3–NEK7 interaction, and changed inflammasome readouts in the cited preclinical systems (In Vitro + Animal Model; PMID 29959312). MSU-driven gout inflammation depends on NLRP3 assembly and downstream IL-1 output.

Novel leap: A characterized oridonin material may reach a gout-relevant human macrophage at a free exposure that engages Cys279 and reduces MSU-triggered output without unacceptable off-target reactivity. No direct evidence establishes this complete human-gout claim.

Why it matters: A positive result would validate a chemically distinct NLRP3 exploit and define the exposure and material specification that sourcing or analog engineering must meet.

Discriminating observation: In human macrophages, cross an exact-material concentration series with MSU challenge and measure free exposure, Cys279 engagement, NLRP3–NEK7 interaction, ASC/caspase-1/GSDMD/IL-1β outputs, AIM2 and NLRC4 controls, viability, and washout. Advance only an exposure that preserves the prespecified selectivity and safety margins.

Falsification path

  1. Mechanism: Failure to reproduce NLRP3 engagement under an identity-verified material closes the direct-mechanism claim for that material and assay.
  2. Gout transfer: Target engagement without a change in MSU-triggered output rejects useful transfer under that exposure.
  3. Exposure: Cellular activity at an exposure not reachable in the intended compartment blocks route translation.
  4. Safety: Loss of selectivity or unacceptable covalent off-target effects blocks advancement even if the inflammasome readout moves.
  5. Combination: Test another arm only after both single agents pass; use a prespecified interaction model rather than inferring additivity from pathway diagrams.

A negative result applies to the tested material, exposure, cell system, and mechanism. It does not decide every oridonin analog or the wider NLRP3 node.

Research-stage evidence map. Phase 0 — Research & Design.